Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Royalty Pharma (RPRX – Research Report) today. The company’s shares opened today at $28.50.
According to TipRanks, Meacham is a 4-star analyst with an average return of 3.2% and a 49.46% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Eli Lilly & Co, and Moderna.
Currently, the analyst consensus on Royalty Pharma is a Strong Buy with an average price target of $46.00.
Based on Royalty Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $596.07 million and a net profit of $887.07 million. In comparison, last year the company earned a revenue of $565.75 million and had a GAAP net loss of $456.08 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Royalty Pharma (RPRX) Company Description:
New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
Read More on RPRX:
